Kv1.3

1

Wan LS et al. Three Minor Diterpenoids with Three Carbon Skeletons from Euphorbia peplus.
Org. Lett., 2016 May 6 , 18 (2166-9).

2

Velez P et al. Ubiquitin ligase Nedd4-2 modulates Kv1.3 current amplitude and ion channel protein targeting.
J. Neurophysiol., 2016 May 4 , (jn.00874.2015).

3

Zhang H et al. Autocrine-Based Selection of Drugs that Target Ion Channels from Combinatorial Venom Peptide Libraries.
Angew. Chem. Int. Ed. Engl., 2016 May 20 , ().

4

Zhang C et al. Molecular basis for the toxin insensitivity of scorpion voltage-gated potassium channel MmKv1.
Biochem. J., 2016 May 1 , 473 (1257-66).

5

Chimote AA et al. Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype.
J. Autoimmun., 2016 May , 69 (86-93).

6

Wright JR et al. Transcriptomic analysis of the ion channelome of human platelets and megakaryocytic cell lines.
Thromb. Haemost., 2016 Jun 9 , 116 ().

7

Balajthy A et al. 7DHC-induced changes of Kv1.3 operation contributes to modified T cell function in Smith-Lemli-Opitz syndrome.
Pflugers Arch., 2016 Jun 17 , ().

8

Reeves TM et al. Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury.
Exp. Neurol., 2016 Jun 11 , ().

9

Olamendi-Portugal T et al. Isolation, chemical and functional characterization of several new K(+)-channel blocking peptides from the venom of the scorpion Centruroides tecomanus.
Toxicon, 2016 Jun 1 , 115 (1-12).

10

Xu J et al. Peimine, a main active ingredient of Fritillaria, exhibits anti-inflammatory and pain suppression properties at the cellular level.
Fitoterapia, 2016 Jun , 111 (1-6).

11

Pethő Z et al. The anti-proliferative effect of cation channel blockers in T lymphocytes depends on the strength of mitogenic stimulation.
Immunol. Lett., 2016 Feb 6 , 171 (60-69).

12

Ma G et al. Study of Small-Molecule-Membrane Protein Binding Kinetics with Nanodisc and Charge-Sensitive Optical Detection.
Anal. Chem., 2016 Feb 16 , 88 (2375-9).

13

Kan XH et al. Kv1.3 potassium channel mediates macrophage migration in atherosclerosis by regulating ERK activity.
Arch. Biochem. Biophys., 2016 Feb 1 , 591 (150-6).

14

Doczi MA et al. Developmental expression of Kv1 voltage-gated potassium channels in the avian hypothalamus.
Neurosci. Lett., 2016 Feb 1 , 616 (182-188).

15

Pucca MB et al. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Immunology, 2016 Feb , 147 (240-50).

16

Laskowski M et al. What do we not know about mitochondrial potassium channels?
Biochim. Biophys. Acta, 2016 Aug , 1857 (1247-57).

17

Pérez-Verdaguer M et al. Caveolin interaction governs Kv1.3 lipid raft targeting.
Sci Rep, 2016 , 6 (22453).

18

Kovach CP et al. Mitochondrial Ultrastructure and Glucose Signaling Pathways Attributed to the Kv1.3 Ion Channel.
Front Physiol, 2016 , 7 (178).

19

Zeng Z et al. A Scorpion Defensin BmKDfsin4 Inhibits Hepatitis B Virus Replication in Vitro.
Toxins (Basel), 2016 , 8 ().

20

Ye F et al. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Toxins (Basel), 2016 , 8 ().

21

Ohya S Physiological Role of K(+) Channels in the Regulation of T Cell Function.
Yakugaku Zasshi, 2016 , 136 (479-83).

22

Siddiqui TA et al. Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
J Neuroinflammation, 2016 , 13 (66).

23

Chen R et al. Peptidomimetic Star Polymers for Targeting Biological Ion Channels.
PLoS ONE, 2016 , 11 (e0152169).

24

Teisseyre A et al. Voltage-Gated Potassium Channels Kv1.3--Potentially New Molecular Target in Cancer Diagnostics and Therapy.
Adv Clin Exp Med, 2015 May-Jun , 24 (517-24).

25

Bhuyan R et al. Molecular dynamics of Kv1.3 ion channel and structural basis of its inhibition by scorpion toxin-OSK1 derivatives.
Biophys. Chem., 2015 Aug-Sep , 203-204 (1-11).

26

Wang X et al. A single-point mutation enhances dual functionality of a scorpion toxin.
Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2015 Sep 7 , 179 (72-78).

27

Murray JK et al. Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
J. Med. Chem., 2015 Sep 10 , 58 (6784-802).

28

Zhang SX et al. [Effect of Kv1.3 and KCa3.1 potassium ion channels on the proliferation and migration of monocytes/macrophages].
Sheng Li Xue Bao, 2015 Oct 25 , 67 (505-12).

29

Xu H et al. Characterization of the direct interaction between KcsA-Kv1.3 and its inhibitors.
Biochim. Biophys. Acta, 2015 Oct , 1848 (1974-80).

30

Kazama I et al. Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.
Inflamm. Res., 2015 Oct , 64 (753-65).

31

Kazama I et al. Chlorpromazine-induced changes in membrane micro-architecture inhibit thrombopoiesis in rat megakaryocytes.
Biochim. Biophys. Acta, 2015 Nov , 1848 (2805-12).

32

Kollár S et al. Impact of aging on calcium influx and potassium channel characteristics of T lymphocytes.
Oncotarget, 2015 May 30 , 6 (13750-6).

33

Zhao Y et al. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Toxins (Basel), 2015 May , 7 (1749-64).

34

Jang SH et al. Nuclear Localization and Functional Characteristics of Voltage-gated Potassium Channel, Kv1.3.
J. Biol. Chem., 2015 Mar 31 , ().

35

Chang SC et al. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
FEBS J., 2015 Jun , 282 (2247-59).

36

Kohl B et al. Solid phase synthesis, NMR structure determination of α-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.
Toxicon, 2015 Jul , 101 (70-8).

37

Rubiolo JA et al. Potassium currents inhibition by gambierol analogs prevents human T lymphocyte activation.
Arch. Toxicol., 2015 Jul , 89 (1119-34).

38

Kazama I Roles of lymphocyte Kv1.3-channels in gut mucosal immune system: Novel therapeutic implications for inflammatory bowel disease.
Med. Hypotheses, 2015 Jul , 85 (61-3).

39

Leanza L et al. Targeting a mitochondrial potassium channel to fight cancer.
Cell Calcium, 2015 Jul , 58 (131-8).

40

Zhou YY et al. Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells.
CNS Neurosci Ther, 2015 Jul , 21 (558-67).

41

Wang X et al. Mesomartoxin, a new K(v)1.2-selective scorpion toxin interacting with the channel selectivity filter.
Biochem. Pharmacol., 2015 Jan 15 , 93 (232-9).

42

Kazama I Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.
J Physiol Sci, 2015 Jan , 65 (25-35).

43

Xiang F et al. Plectasin, first animal toxin-like fungal defensin blocking potassium channels through recognizing channel pore region.
Toxins (Basel), 2015 Jan , 7 (34-42).

44

Pennington MW et al. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Mar Drugs, 2015 Jan , 13 (529-42).

45

Yang W et al. Endogenous animal toxin-like human β-defensin 2 inhibits own K(+) channels through interaction with channel extracellular pore region.
Cell. Mol. Life Sci., 2015 Feb , 72 (845-53).

46

Silver K et al. Inhibition of Kv channel expression by NSAIDs depolarizes membrane potential and inhibits cell migration by disrupting calpain signaling.
Biochem. Pharmacol., 2015 Dec 15 , 98 (614-28).

47

Zhao R et al. Designer and natural peptide toxin blockers of the KcsA potassium channel identified by phage display.
Proc. Natl. Acad. Sci. U.S.A., 2015 Dec 15 , 112 (E7013-21).

48

Frolov RV et al. Evidence of more ion channels inhibited by celecoxib: KV1.3 and L-type Ca (2+) channels.
BMC Res Notes, 2015 Dec , 8 (1023).

49

Grishkan IV et al. Antigenic Stimulation of Kv1.3-Deficient Th Cells Gives Rise to a Population of Foxp3-Independent T Cells with Suppressive Properties.
J. Immunol., 2015 Aug 15 , 195 (1399-407).

50

Chen J et al. SjAPI-2 is the first member of a new neurotoxin family with Ascaris-type fold and KCNQ1 inhibitory activity.
Int. J. Biol. Macromol., 2015 Aug , 79 (504-10).

51

Zúñiga-García V et al. Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development.
Dig. Dis. Sci., 2015 Apr 5 , ().

52

Sforna L et al. Expression and function of a CP339,818-sensitive K⁺ current in a subpopulation of putative nociceptive neurons from adult mouse trigeminal ganglia.
J. Neurophysiol., 2015 Apr 1 , 113 (2653-65).

53

Hosseinzadeh Z et al. Up-regulation of Kv1.3 channels by janus kinase 2.
J. Membr. Biol., 2015 Apr , 248 (309-17).

54

Jiang Y et al. Different solvent fractions of Acanthopanax senticosus harms exert antioxidant and anti-inflammatory activities and inhibit the human Kv1.3 channel.
J Med Food, 2015 Apr , 18 (468-75).

55

Rangaraju S et al. Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease.
J. Alzheimers Dis., 2015 , 44 (797-808).

56

Bittner S et al. Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms.
Int J Mol Sci, 2015 , 16 (16880-96).

57

Bartok A et al. An engineered scorpion toxin analogue with improved Kv1.3 selectivity displays reduced conformational flexibility.
Sci Rep, 2015 , 5 (18397).

58

Charolidi N et al. Microglial Kv1.3 Channels and P2Y12 Receptors Differentially Regulate Cytokine and Chemokine Release from Brain Slices of Young Adult and Aged Mice.
PLoS ONE, 2015 , 10 (e0128463).

59

Kazama I Roles of lymphocyte kv1.3-channels in the pathogenesis of renal diseases and novel therapeutic implications of targeting the channels.
Mediators Inflamm., 2015 , 2015 (436572).

60

Chen Z et al. Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel.
Sci Rep, 2015 , 5 (9881).

61

Frolov RV et al. Evidence of more ion channels inhibited by celecoxib: KV1.3 and L-type Ca(2+) channels.
BMC Res Notes, 2015 , 8 (62).

62

Meredith FL et al. Kv1 channels and neural processing in vestibular calyx afferents.
Front Syst Neurosci, 2015 , 9 (85).

63

Bartok A et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon, 2014 Sep , 87 (6-16).

64

Kuyucak S et al. Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics.
Future Med Chem, 2014 Oct , 6 (1645-58).

65

Carrisoza-Gaytán R et al. Differential expression of the Kv1 voltage-gated potassium channel family in the rat nephron.
J. Mol. Histol., 2014 Oct , 45 (583-97).

66

Koch Hansen L et al. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.
J Crohns Colitis, 2014 Nov , 8 (1378-91).

67

Hansen LK The role of T cell potassium channels, KV1.3 and KCa3.1, in the inflammatory cascade in ulcerative colitis.
Dan Med J, 2014 Nov , 61 (B4946).

68

Delaney E et al. Determinants of pore folding in potassium channel biogenesis.
Proc. Natl. Acad. Sci. U.S.A., 2014 Mar 25 , 111 (4620-5).

69

Panyi G et al. Ion channels and anti-cancer immunity.
Philos. Trans. R. Soc. Lond., B, Biol. Sci., 2014 Mar 19 , 369 (20130106).

70

Cerni FA et al. Electrophysiological characterization of Ts6 and Ts7, K⁺ channel toxins isolated through an improved Tityus serrulatus venom purification procedure.
Toxins (Basel), 2014 Mar , 6 (892-913).

71

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

72

Chhabra S et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
FASEB J., 2014 Jun 2 , ().

73

Edwards W et al. Targeting the Ion Channel Kv1.3 with Scorpion Venom Peptides Engineered for Potency, Selectivity, and Half-life.
J. Biol. Chem., 2014 Jun 17 , ().

74

Luna-Ramírez K et al. Structure, molecular modeling, and function of the novel potassium channel blocker urotoxin isolated from the venom of the Australian scorpion Urodacus yaschenkoi.
Mol. Pharmacol., 2014 Jul , 86 (28-41).

75

Orban C et al. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Cytometry A, 2014 Jul , 85 (636-41).

76

Rashid MH et al. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
J Phys Chem B, 2014 Jan 23 , 118 (707-16).

77

Hamilton DL et al. Kv1.3 inhibitors have differential effects on glucose uptake and AMPK activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle.
J Physiol Sci, 2014 Jan , 64 (13-20).

78

Hoang AN et al. Vietnamese Heterometrus laoticus scorpion venom: evidence for analgesic and anti-inflammatory activity and isolation of new polypeptide toxin acting on Kv1.3 potassium channel.
Toxicon, 2014 Jan , 77 (40-8).

79

Xie C et al. Kv1.3 potassium channel-blocking toxin Ctri9577, novel gating modifier of Kv4.3 potassium channel from the scorpion toxin family.
Biochem. Biophys. Res. Commun., 2014 Feb 14 , 444 (406-10).

80

Vu TT et al. Soluble prokaryotic expression and purification of crotamine using an N-terminal maltose-binding protein tag.
Toxicon, 2014 Dec 15 , 92 (157-65).

81

Kundu-Raychaudhuri S et al. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.
J. Autoimmun., 2014 Dec , 55 (63-72).

82

Cidad P et al. K+ channels expression in hypertension after arterial injury, and effect of selective Kv1.3 blockade with PAP-1 on intimal hyperplasia formation.
Cardiovasc Drugs Ther, 2014 Dec , 28 (501-11).

83

Ahmed M et al. Down-regulation of K⁺ channels by human parvovirus B19 capsid protein VP1.
Biochem. Biophys. Res. Commun., 2014 Aug 8 , 450 (1396-401).

84

Zhu J et al. The Kv1.3 potassium channel is localized to the cis-Golgi and Kv1.6 is localized to the endoplasmic reticulum in rat astrocytes.
FEBS J., 2014 Aug , 281 (3433-45).

85

Kazama I et al. HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes.
Pharmacol Rep, 2014 Aug , 66 (712-7).

86

Dufour MA et al. Somatodendritic ion channel expression in substantia nigra pars compacta dopaminergic neurons across postnatal development.
J. Neurosci. Res., 2014 Aug , 92 (981-99).

87

Chen Z et al. Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues.
Biochem. Biophys. Res. Commun., 2014 Apr 25 , 447 (70-6).

88

Galea CA et al. Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking.
Cell. Mol. Life Sci., 2014 Apr , 71 (1191-210).

89

Tao J et al. Recombinant expression and functional characterization of martentoxin: a selective inhibitor for BK channel (α + β4).
Toxins (Basel), 2014 Apr , 6 (1419-33).

90

Peng Y et al. Blockade of Kv1.3 channels ameliorates radiation-induced brain injury.
Neuro-oncology, 2014 Apr , 16 (528-39).

91

Wang J et al. Effect of methamphetamine on the microglial damage: role of potassium channel Kv1.3.
PLoS ONE, 2014 , 9 (e88642).

92

Simma N et al. NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells.
Cell Commun. Signal, 2014 , 12 (75).

93

Folyovich A et al. Kv1.3 lymphocyte potassium channel inhibition as a potential novel therapeutic target in acute ischemic stroke.
CNS Neurol Disord Drug Targets, 2014 , 13 (801-6).

94

Kazama I et al. Benidipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure.
Nephron Exp. Nephrol., 2014 , 128 (67-79).

95

Almilaji A et al. Regulation of the voltage gated K channel Kv1.3 by recombinant human klotho protein.
Kidney Blood Press. Res., 2014 , 39 (609-22).

96

Wang W et al. Effects of voltage-gated K+ channel on cell proliferation in multiple myeloma.
ScientificWorldJournal, 2014 , 2014 (785140).

97

Chen R et al. Binding modes of two scorpion toxins to the voltage-gated potassium channel kv1.3 revealed from molecular dynamics.
Toxins (Basel), 2014 , 6 (2149-61).

98

Zhao N et al. Acacetin blocks kv1.3 channels and inhibits human T cell activation.
Cell. Physiol. Biochem., 2014 , 34 (1359-72).

99

Anh HN et al. Hetlaxin, a new toxin from the Heterometrus laoticus scorpion venom, interacts with voltage-gated potassium channel Kv1.3.
Dokl. Biochem. Biophys., 2013 Mar-Apr , 449 (109-11).

100

Hajdu P et al. Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity.
Biomaterials, 2013 Sep 26 , ().

101

Szilágyi O et al. The role of PSD-95 in the rearrangement of Kv1.3 channels to the immunological synapse.
Pflugers Arch., 2013 Sep , 465 (1341-53).

102

Lian YT et al. Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities.
Phytother Res, 2013 Sep , 27 (1321-7).

103

Lioudyno MI et al. Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics.
J. Neurosci., 2013 Oct 9 , 33 (16310-22).

104

Vallejo-Gracia A et al. Emerging role for the voltage-dependent K+ channel Kv1.5 in B-lymphocyte physiology: expression associated with human lymphoma malignancy.
J. Leukoc. Biol., 2013 Oct , 94 (779-89).

105

Orts DJ et al. BcsTx3 is a founder of a novel sea anemone toxin family of potassium channel blocker.
FEBS J., 2013 Oct , 280 (4839-52).

106

Combs DJ et al. Tuning voltage-gated channel activity and cellular excitability with a sphingomyelinase.
J. Gen. Physiol., 2013 Oct , 142 (367-380).

107

Duque A et al. Expression of Kv1.3 potassium channels regulates density of cortical interneurons.
Dev Neurobiol, 2013 Nov , 73 (841-55).

108

Leanza L et al. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Curr. Pharm. Des., 2013 May 16 , ().

109

Tucker K et al. Glucose sensitivity of mouse olfactory bulb neurons is conveyed by a voltage-gated potassium channel.
J. Physiol. (Lond.), 2013 May 15 , 591 (2541-61).

110

Hautz T et al. Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - a pilot study.
Transpl. Int., 2013 May , 26 (552-61).

111

Wang J et al. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
Pharmacotherapy, 2013 May , 33 (515-28).

112

Kendel Y et al. Venomous secretions from marine snails of the Terebridae family target acetylcholine receptors.
Toxins (Basel), 2013 May , 5 (1043-50).

113

Weingarth M et al. Structural determinants of specific lipid binding to potassium channels.
J. Am. Chem. Soc., 2013 Mar 13 , 135 (3983-8).

114

Nguyen HM et al. Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease.
J. Biol. Chem., 2013 Mar 1 , 288 (6451-64).

115

Bajnok A et al. Analysis by flow cytometry of calcium influx kinetics in peripheral lymphocytes of patients with rheumatoid arthritis.
Cytometry A, 2013 Mar , 83 (287-93).

116

Feng J et al. Expression and characterization of a novel scorpine-like peptide Ev37, from the scorpion Euscorpiops validus.
Protein Expr. Purif., 2013 Mar , 88 (127-33).

117

Kudryashova KS et al. Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1.3 ligand screening and study.
Anal Bioanal Chem, 2013 Mar , 405 (2379-89).

118

Zhang L et al. CMYA5: a new potential substrate of Kcna3 in human heart.
Acta Biochim. Biophys. Sin. (Shanghai), 2013 Mar , 45 (236-8).

119

Orts DJ et al. Biochemical and electrophysiological characterization of two sea anemone type 1 potassium toxins from a geographically distant population of Bunodosoma caissarum.
Mar Drugs, 2013 Mar , 11 (655-79).

120

Toldi G et al. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Immunobiology, 2013 Mar , 218 (311-6).

121

Upadhyay SK et al. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jun 11 , 110 (E2239-48).

122

Kazama I et al. Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes.
Pharm Biol, 2013 Jun , 51 (760-5).

123

Fu XX et al. 18β-Glycyrrhetinic acid potently inhibits Kv1.3 potassium channels and T cell activation in human Jurkat T cells.
J Ethnopharmacol, 2013 Jul 9 , 148 (647-54).

124

Hilder TA et al. Designing a C84 fullerene as a specific voltage-gated sodium channel blocker.
Nanoscale Res Lett, 2013 Jul 16 , 8 (323).

125

Tian Y et al. Increased proliferation of human bladder smooth muscle cells is mediated by physiological cyclic stretch via the PI3K‑SGK1‑Kv1.3 pathway.
Mol Med Rep, 2013 Jul , 8 (294-8).

126

Somodi S et al. Analysis of the K+ current in human CD4+ T lymphocytes in hypercholesterolemic state.
Cell. Immunol., 2013 Jan , 281 (20-6).

127

Lang F et al. Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1.
FASEB J., 2013 Jan , 27 (3-12).

128

Yang Y et al. Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.
J. Lipid Res., 2013 Jan , 54 (34-43).

129

You MH et al. Voltage-gated K+ channels in adipogenic differentiation of bone marrow-derived human mesenchymal stem cells.
Acta Pharmacol. Sin., 2013 Jan , 34 (129-36).

130

Yamamoto Y et al. Amiodarone inhibits tissue factor expression in monocytic THP-1 cells.
Eur. J. Pharmacol., 2013 Feb 15 , 701 (14-9).

131

Kazama I et al. Benidipine persistently inhibits delayed rectifier K(+)-channel currents in murine thymocytes.
Immunopharmacol Immunotoxicol, 2013 Feb , 35 (28-33).

132

Kahlfuß S et al. Immunosuppression by NMDA-Receptor Antagonists is Mediated Through Inhibition of Kv1.3 and KCa3.1 Channels in T cells.
Mol. Cell. Biol., 2013 Dec 16 , ().

133

Chimote AA et al. Selective Inhibition of KCa3.1 Channels Mediates Adenosine Regulation of the Motility of Human T Cells.
J. Immunol., 2013 Dec 15 , 191 (6273-80).

134

Martínez-Mármol R et al. A non-canonical di-acidic signal at the C-terminus of Kv1.3 determines anterograde trafficking and surface expression.
J. Cell. Sci., 2013 Dec 15 , 126 (5681-91).

135

Ueyama A et al. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Clin. Exp. Dermatol., 2013 Dec , 38 (897-903).

136

Ishii T et al. Sequestosome1/p62: a regulator of redox-sensitive voltage-activated potassium channels, arterial remodeling, inflammation, and neurite outgrowth.
Free Radic. Biol. Med., 2013 Dec , 65 (102-16).

137

Zhang QB et al. [Voltage-dependent potassium channel and calcium-activated potassium channel current changes of peripheral blood T-lymphocytes from hypertensive patients in Xinjiang Kazakh].
Zhonghua Xin Xue Guan Bing Za Zhi, 2013 Dec , 41 (1020-4).

138

Nguyen W Novel Kv1.3 blockers for immunosuppression: W02012155199.
Expert Opin Ther Pat, 2013 Aug 23 , ().

139

Dang B et al. Native chemical ligation at Asx-Cys, Glx-Cys: chemical synthesis and high-resolution X-ray structure of ShK toxin by racemic protein crystallography.
J. Am. Chem. Soc., 2013 Aug 14 , 135 (11911-9).

140

Leanza L et al. Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.
Leukemia, 2013 Aug , 27 (1782-5).

141

Gilhar A et al. Blocking potassium channels (Kv1.3): a new treatment option for alopecia areata?
J. Invest. Dermatol., 2013 Aug , 133 (2088-91).

142

Schwartz EF et al. OcyKTx2, a new K⁺-channel toxin characterized from the venom of the scorpion Opisthacanthus cayaporum.
Peptides, 2013 Aug , 46 (40-6).

143

Salem KA et al. Effects of exercise training on excitation-contraction coupling and related mRNA expression in hearts of Goto-Kakizaki type 2 diabetic rats.
Mol. Cell. Biochem., 2013 Aug , 380 (83-96).

144

Johnson MC et al. Odor enrichment sculpts the abundance of olfactory bulb mitral cells.
Neurosci. Lett., 2013 Apr 29 , 541 (173-8).

145

Yamada J et al. Novel objective classification of reactive microglia following hypoglossal axotomy using hierarchical cluster analysis.
J. Comp. Neurol., 2013 Apr 1 , 521 (1184-201).

146

Fujii M et al. New screening system for selective blockers of voltage-gated K(+) channels using recombinant cell lines dying upon single action potential.
J. Pharmacol. Sci., 2013 , 123 (147-58).

147

Leanza L et al. Intracellular ion channels and cancer.
Front Physiol, 2013 , 4 (227).

148

Zhao N et al. Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells.
PLoS ONE, 2013 , 8 (e64629).

149

Wu J et al. Voltage-gated potassium channel Kv1.3 is highly expressed in human osteosarcoma and promotes osteosarcoma growth.
Int J Mol Sci, 2013 , 14 (19245-56).

150

Liu J et al. HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity.
PLoS ONE, 2013 , 8 (e64904).

151

Hu L et al. Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
PLoS ONE, 2013 , 8 (e54267).

152

Koshy S et al. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes.
PLoS ONE, 2013 , 8 (e76740).

153

Rashid MH et al. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
PLoS ONE, 2013 , 8 (e78712).

154

Chen YJ et al. The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.
PLoS ONE, 2013 , 8 (e81006).

155

Tarcha EJ et al. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
J. Pharmacol. Exp. Ther., 2012 Sep , 342 (642-53).

156

Wang Y et al. Molecular cloning and functional analysis of a voltage-gated potassium channel in lymphocytes from sea perch, Lateolabrax japonicus.
Fish Shellfish Immunol., 2012 Sep , 33 (605-13).

157

Tucker KR et al. Olfactory ability and object memory in three mouse models of varying body weight, metabolic hormones, and adiposity.
Physiol. Behav., 2012 Oct 10 , 107 (424-32).

158

Kazama I et al. Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channel currents in murine thymocytes.
Immunopharmacol Immunotoxicol, 2012 Oct , 34 (874-8).

159

Izsepi E et al. Membrane microdomain organization, calcium signal, and NFAT activation as an important axis in polarized Th cell function.
Cytometry A, 2012 Nov 26 , ().

160

Pennington MW et al. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
FEBS Lett., 2012 Nov 16 , 586 (3996-4001).

161

Xie S et al. Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.
, 2012 May 8 , ().

162

Gurrola GB et al. Structure, Function, and Chemical Synthesis of Vaejovis mexicanus Peptide 24: A Novel Potent Blocker of Kv1.3 Potassium Channels of Human T Lymphocytes.
, 2012 May 7 , ().

163

Nikouee A et al. Charybdotoxin and margatoxin acting on the human voltage-gated potassium channel hKv1.3 and its H399N mutant: an experimental and computational comparison.
J Phys Chem B, 2012 May 3 , 116 (5132-40).

164

Varga Z et al. Vm24, a Natural Immunosuppressant Peptide Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells.
, 2012 May 23 , ().

165

Gocke AR et al. Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis.
, 2012 May 11 , ().

166

Kazama I et al. Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes.
J Physiol Sci, 2012 May , 62 (267-74).

167

He S et al. Increased Kv1 channel expression may contribute to decreased sIPSC frequency following chronic inhibition of NR2B-containing NMDAR.
Neuropsychopharmacology, 2012 May , 37 (1338-56).

168

Kinoshita M et al. Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands.
, 2012 Mar 6 , ().

169

Stehling EG et al. Looking over toxin-K(+) channel interactions. Clues from the structural and functional characterization of α-KTx toxin Tc32, a Kv1.3 channel blocker.
Biochemistry, 2012 Mar 6 , 51 (1885-94).

170

Chen R et al. Engineering a potent and specific blocker of voltage-gated potassium channel Kv1.3, a target for autoimmune diseases.
Biochemistry, 2012 Mar 6 , 51 (1976-82).

171

Lee SK et al. Single cell analysis of voltage-gated potassium channels that determines neuronal types of rat hypothalamic paraventricular nucleus neurons.
Neuroscience, 2012 Mar 15 , 205 (49-62).

172

Cidad P et al. Kv1.3 Channels Can Modulate Cell Proliferation During Phenotypic Switch by an Ion-Flux Independent Mechanism.
, 2012 Mar 1 , ().

173

Bielanska J et al. Differential expression of Kv1.3 and Kv1.5 voltage-dependent K+ channels in human skeletal muscle sarcomas.
Cancer Invest., 2012 Mar , 30 (203-8).

174

Mahaut-Smith MP The unique contribution of ion channels to platelet and megakaryocyte function.
, 2012 Jun 28 , ().

175

Kim BS et al. Argonaute2 regulation for K+ channel-mediated human adipose tissue-derived stromal cells self-renewal and survival in nucleus.
Stem Cells Dev., 2012 Jul 1 , 21 (1736-48).

176

Leanza L et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells.
EMBO Mol Med, 2012 Jul , 4 (577-93).

177

Hu L et al. Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling.
J. Biol. Chem., 2012 Jan 6 , 287 (1261-8).

178

Chimote AA et al. Disruption of kv1.3 channel forward vesicular trafficking by hypoxia in human T lymphocytes.
J. Biol. Chem., 2012 Jan 13 , 287 (2055-67).

179

Kuras Z et al. Modulation of Kv1.3 channels by protein kinase A I in T lymphocytes is mediated by the Disc large 1 (Dlg1)- tyrosine kinase Lck complex.
, 2012 Feb 29 , ().

180

Xu R et al. Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome.
Clin. Immunol., 2012 Feb , 142 (209-17).

181

Wang LH et al. Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors.
Biochim. Biophys. Acta, 2012 Feb , 1823 (505-13).

182

Lang F et al. Serum- and glucocorticoid-inducible kinase 1 in the regulation of renal and extrarenal potassium transport.
Clin. Exp. Nephrol., 2012 Feb , 16 (73-80).

183

Nguyen W et al. Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.
Bioorg. Med. Chem. Lett., 2012 Dec 1 , 22 (7106-9).

184

Gąsiorowska J et al. The influence of 8-prenylnaringenin on the activity of voltage-gated Kv1.3 potassium channels in human Jurkat T cells.
Cell. Mol. Biol. Lett., 2012 Dec , 17 (559-70).

185

Li Z et al. Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.
J. Biol. Chem., 2012 Aug 24 , 287 (29479-94).

186

Zhu J et al. N-glycosylation promotes the cell surface expression of Kv1.3 potassium channels.
FEBS J., 2012 Aug , 279 (2632-44).

187

Lei X et al. [Diclofenac inhibits Kv1.3 and Kir2.1 expressions in human macrophages and affects the membrane potential and foam cell formation].
Nan Fang Yi Ke Da Xue Xue Bao, 2012 Aug , 32 (1067-73).

188

Tucker K et al. Diet-induced obesity resistance of Kv1.3-/- mice is olfactory bulb dependent.
J. Neuroendocrinol., 2012 Aug , 24 (1087-95).

189

Rashid MH et al. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.
J Phys Chem B, 2012 Apr 26 , 116 (4812-22).

190

Chen ZY et al. Hg1, novel peptide inhibitor specific for Kv1.3 channels from first scorpion Kunitz-type potassium channel toxin family.
J. Biol. Chem., 2012 Apr 20 , 287 (13813-21).

191

Huang CY et al. Co-expression of high-voltage-activated ion channels Kv3.4 and Cav1.2 in pioneer axons during pathfinding in the developing rat forebrain.
, 2012 Apr 2 , ().

192

Yang XF et al. The antibody targeting the e314 Peptide of human kv1.3 pore region serves as a novel, potent and specific channel blocker.
PLoS ONE, 2012 , 7 (e36379).

193

Lioudyno MI et al. Effect of synthetic aβ Peptide oligomers and fluorinated solvents on kv1.3 channel properties and membrane conductance.
PLoS ONE, 2012 , 7 (e35090).

194

Liu J et al. Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity.
Cell Death Dis, 2012 , 3 (e254).

195

Leanza L et al. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels.
Curr. Med. Chem., 2012 , 19 (5394-404).

196

Felipe A et al. Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention.
Curr. Med. Chem., 2012 , 19 (661-74).

197

Kuras Z et al. KCa3.1 and TRPM7 channels at the uropod regulate migration of activated human T cells.
PLoS ONE, 2012 , 7 (e43859).

198

Chen ZY et al. Structural and functional diversity of acidic scorpion potassium channel toxins.
PLoS ONE, 2012 , 7 (e35154).

199

Chen R et al. Structural basis of the selective block of Kv1.2 by maurotoxin from computer simulations.
PLoS ONE, 2012 , 7 (e47253).

200

Wang T et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel.
PLoS ONE, 2012 , 7 (e43950).

201

Khabiri M et al. Charybdotoxin unbinding from the mKv1.3 potassium channel: a combined computational and experimental study.
J Phys Chem B, 2011 Oct 6 , 115 (11490-500).

202

Doczi MA et al. A C-terminal PDZ binding domain modulates the function and localization of Kv1.3 channels.
Exp. Cell Res., 2011 Oct 1 , 317 (2333-41).

203

Beeton C et al. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Inflamm Allergy Drug Targets, 2011 Oct 1 , 10 (313-21).

204

Reneer MC et al. Peripherally induced human regulatory T cells uncouple Kv1.3 activation from TCR-associated signaling.
Eur. J. Immunol., 2011 Nov , 41 (3170-5).

205

Gojkovic-Bukarica L et al. Effect of potassium channel opener pinacidil on the contractions elicited electrically or by noradrenaline in the human radial artery.
Eur. J. Pharmacol., 2011 Mar 11 , 654 (266-73).

206

Hao B et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.
Xenobiotica, 2011 Mar , 41 (198-211).

207

Park KS et al. Identification and functional characterization of ion channels in CD34(+) hematopoietic stem cells from human peripheral blood.
, 2011 Jun 1 , ().

208

Ramirez-Navarro A et al. Kv1.3 channels regulate synaptic transmission in the nucleus of solitary tract.
J. Neurophysiol., 2011 Jun , 105 (2772-80).

209

Gao B et al. Molecular divergence of two orthologous scorpion toxins affecting potassium channels.
Comp. Biochem. Physiol., Part A Mol. Integr. Physiol., 2011 Jul , 159 (313-21).

210

Nittner-Marszalska M et al. Influence of specific immunotherapy on the activity of human T lymphocyte Kv1.3 voltage-gated potassium channels in insect venom allergic patients.
J. Membr. Biol., 2011 Jul , 242 (23-9).

211

Jang SH et al. Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo.
Eur. J. Pharmacol., 2011 Jan 25 , 651 (26-32).

212

Zeng R et al. Differentiation of Human Bone Marrow Mesenchymal Stem Cells into Neuron-like Cells in Vitro.
, 2011 Jan 25 , ().

213

Gilhar A et al. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model.
J. Invest. Dermatol., 2011 Jan , 131 (118-24).

214

Chen Z et al. ImKTx1, a new Kv1.3 channel blocker with a unique primary structure.
, 2011 Feb 9 , ().

215

Schilling T et al. Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia.
, 2011 Feb 14 , ().

216

Cheong A et al. Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers.
Cardiovasc. Res., 2011 Feb 1 , 89 (282-9).

217

Han S et al. ImKTx88, a novel selective Kv1.3 channel blocker derived from the scorpion Isometrus maculates.
Toxicon, 2011 Feb , 57 (348-55).

218

Zhu S et al. Molecular diversity and functional evolution of scorpion potassium channel toxins.
Mol. Cell Proteomics, 2011 Feb , 10 (M110.002832).

219

Toldi G et al. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
Am. J. Reprod. Immunol., 2011 Feb , 65 (154-63).

220

Chen R et al. Modeling the binding of three toxins to the voltage-gated potassium channel (Kv1.3).
Biophys. J., 2011 Dec 7 , 101 (2652-60).

221

Rodríguez-Fernández T et al. Electrochemical strategy to scout 1,4-naphthoquinones effect on voltage gated potassium channels.
, 2011 Dec 30 , ().

222

Roepke TK et al. KCNE2 forms potassium channels with KCNA3 and KCNQ1 in the choroid plexus epithelium.
FASEB J., 2011 Dec , 25 (4264-73).

223

Novakovic A et al. Different K+ channels are involved in relaxation of arterial and venous graft induced by nicorandil.
J. Cardiovasc. Pharmacol., 2011 Dec , 58 (602-8).

224

Chi V et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
, 2011 Aug 12 , ().

225

Straub SV et al. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues.
Am. J. Physiol. Endocrinol. Metab., 2011 Aug , 301 (E380-90).

226

Fortin DL et al. Optogenetic photochemical control of designer K+ channels in mammalian neurons.
, 2011 Apr 27 , ().

227

Prütting S et al. A novel current pathway parallel to the central pore in a mutant voltage gated potassium channel.
, 2011 Apr 15 , ().

228

Rossokhin A et al. Why does the inner-helix mutation A413C double the stoichiometry of Kv1.3 channel block by emopamil but not by verapamil?
Mol. Pharmacol., 2011 Apr , 79 (681-91).

229

Fadool DA et al. Mitral cells of the olfactory bulb perform metabolic sensing and are disrupted by obesity at the level of the Kv1.3 ion channel.
PLoS ONE, 2011 , 6 (e24921).

230

Ota M et al. Polymorphism in the KCNA3 gene is associated with susceptibility to autoimmune pancreatitis in the Japanese population.
Dis. Markers, 2011 , 31 (223-9).

231

Sassi N et al. An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1.
Biochim. Biophys. Acta, 2010 Jun-Jul , 1797 (1260-7).

232

Gulbins E et al. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes.
Biochim. Biophys. Acta, 2010 Jun-Jul , 1797 (1251-9).

233

Toldi G et al. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
Immunol. Lett., 2010 Sep 6 , 133 (35-41).

234

Villalonga N et al. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.
Biochem. Pharmacol., 2010 Sep 15 , 80 (858-66).

235

Toldi G et al. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
Int. Immunol., 2010 Sep , 22 (769-74).

236

Choi BH et al. Kv1.3: a potential pharmacological target for diabetes.
Acta Pharmacol. Sin., 2010 Sep , 31 (1031-5).

237

Tyan L et al. Inhibition of voltage-gated K+ channels in dendritic cells by rapamycin.
, 2010 Oct 6 , ().

238

Haffner CD et al. Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2.
, 2010 Oct 23 , ().

239

Cavallin MA et al. State-dependent sculpting of olfactory sensory neurons is attributed to sensory enrichment, odor deprivation, and aging.
Neurosci. Lett., 2010 Oct 11 , 483 (90-5).

240

Szabò I et al. Single-point mutations of a lysine residue change function of Bax and Bcl-x(L) expressed in Bax- and Bak-less mouse embryonic fibroblasts: novel insights into the molecular mechanisms of Bax-induced apoptosis.
, 2010 Oct 1 , ().

241

Szabò I et al. Contribution of voltage-gated potassium channels to the regulation of apoptosis.
FEBS Lett., 2010 May 17 , 584 (2049-56).

242

Cheng Y et al. Interaction of mitochondrial potassium channels with the permeability transition pore.
FEBS Lett., 2010 May 17 , 584 (2005-12).

243

McCloskey C et al. Kv1.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count.
J. Physiol. (Lond.), 2010 May 1 , 588 (1399-406).

244

Rangaraju S et al. Potassium channel modulation by a toxin domain in matrix metalloprotease 23.
J. Biol. Chem., 2010 Mar 19 , 285 (9124-36).

245

Cidad P et al. Characterization of Ion Channels Involved in the Proliferative Response of Femoral Artery Smooth Muscle Cells.
, 2010 Mar 18 , ().

246

Tu LW et al. A folding zone in the ribosomal exit tunnel for Kv1.3 helix formation.
J. Mol. Biol., 2010 Mar 12 , 396 (1346-60).

247

Bednarczyk P et al. Identification of a voltage-gated potassium channel in gerbil hippocampal mitochondria.
, 2010 Jun 3 , ().

248

Liu J et al. [Expression and properties of potassium channels in human mammary epithelial cell line MCF10A and its possible role in proliferation].
Sheng Li Xue Bao, 2010 Jun 25 , 62 (203-9).

249

Emerson M Kv1.3: the perfect opening of the platelet voltage gate.
J. Physiol. (Lond.), 2010 Jun 1 , 588 (1809).

250

Jackson WF KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation.
Arterioscler. Thromb. Vasc. Biol., 2010 Jun , 30 (1073-4).

251

Lu S et al. The slack sodium-activated potassium channel provides a major outward current in olfactory neurons of Kv1.3-/- super-smeller mice.
J. Neurophysiol., 2010 Jun , 103 (3311-9).

252

Zimin PI et al. Potassium Channel Block by a Tripartite Complex of Two Cationophilic Ligands and a Potassium Ion.
, 2010 Jul 2 , ().

253

Aguilar MB et al. Peptide sr11a from Conus spurius is a novel peptide blocker for Kv1 potassium channels.
Peptides, 2010 Jul , 31 (1287-91).

254

Carrisoza-Gaytán R et al. Potassium secretion by voltage-gated potassium channel Kv1.3 in the rat kidney.
Am. J. Physiol. Renal Physiol., 2010 Jul , 299 (F255-64).

255

Hajdu P et al. Answer to the "Comment on functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse" by Stefan Bittner et al. [Immunol. Lett. 125 (Aug 15 (2)) (2009) 156-157].
, 2010 Jan 15 , ().

256

Pang B et al. TNF-alpha inhibits the CD3-mediated upregulation of voltage-gated K+ channel (Kv1.3) in human T cells.
Biochem. Biophys. Res. Commun., 2010 Jan 1 , 391 (909-14).

257

Nicolaou SA et al. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.
Cell Calcium, 2010 Jan , 47 (19-28).

258

Koeberle PD et al. Kv1.1 and Kv1.3 channels contribute to the degeneration of retinal ganglion cells after optic nerve transection in vivo.
Cell Death Differ., 2010 Jan , 17 (134-44).

259

Liu K et al. High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay.
J Biomol Screen, 2010 Feb , 15 (185-95).

260

Haffner CD et al. N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1.
Bioorg. Med. Chem. Lett., 2010 Dec 1 , 20 (6983-8).

261

Wulff H Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.
Expert Opin Ther Pat, 2010 Dec , 20 (1759-65).

262

Hyodo T et al. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis.
Am. J. Physiol. Renal Physiol., 2010 Dec , 299 (F1258-69).

263

Luo J et al. [Difference in the expression of Kv channel in lymphocytes between spontaneously hypertensive rats and Wistar rats].
Sheng Li Xue Bao, 2010 Aug 25 , 62 (382-6).

264

Gazula VR et al. Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons.
J. Comp. Neurol., 2010 Aug 15 , 518 (3205-20).

265

Gao B et al. A potent potassium channel blocker from Mesobuthus eupeus scorpion venom.
, 2010 Aug 13 , ().

266

Luo J et al. [Effects of telmisartan on 4-Aminopyridine-sensitive voltage dependant potassium channel of lymphocyte derived from spontaneously hypertensive rat].
Zhonghua Xin Xue Guan Bing Za Zhi, 2010 Aug , 38 (751-4).

267

Wang T et al. Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers.
J. Neurosci., 2010 Apr 7 , 30 (5020-7).

268

Nguyen W et al. Use of Kv1.3 blockers for inflammatory skin conditions.
Curr. Med. Chem., 2010 , 17 (2882-96).

269

Tucker K et al. The Olfactory Bulb: A Metabolic Sensor of Brain Insulin and Glucose Concentrations via a Voltage-Gated Potassium Channel.
Results Probl Cell Differ, 2010 , 52 (147-57).

270

Bielanska J et al. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human fetus.
Cell. Physiol. Biochem., 2010 , 26 (219-26).

271

Hunter C et al. Selective inhibitors of Kv11.1 regulate IL-6 expression by macrophages in response to TLR/IL-1R ligands.
ScientificWorldJournal, 2010 , 10 (1580-96).

272

Grgic I et al. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection.
Transplant. Proc., 2009 Jul-Aug , 41 (2601-6).

273

Papp F et al. Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.
Toxicon, 2009 Sep 15 , 54 (379-89).

274

Cahalan MD et al. The functional network of ion channels in T lymphocytes.
Immunol. Rev., 2009 Sep , 231 (59-87).

275

Guthoff M et al. Effect of genetic variation in Kv1.3 on olfactory function.
Diabetes Metab. Res. Rev., 2009 Sep , 25 (523-7).

276

Buckinx R et al. Morphological changes do not reflect biochemical and functional differentiation in OLN-93 oligodendroglial cells.
J. Neurosci. Methods, 2009 Oct 30 , 184 (1-9).

277

Solé L et al. KCNE4 suppresses Kv1.3 currents by modulating trafficking, surface expression and channel gating.
J. Cell. Sci., 2009 Oct 15 , 122 (3738-48).

278

Zsiros E et al. Developmental switch of the expression of ion channels in human dendritic cells.
J. Immunol., 2009 Oct 1 , 183 (4483-92).

279

Nicolaou SA et al. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes.
J. Immunol., 2009 Nov 15 , 183 (6296-302).

280

Marks DR et al. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors.
J. Neurosci., 2009 May 20 , 29 (6734-51).

281

Bodendiek SB et al. 4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.
, 2009 May , 44 (1838-52).

282

Matsushita Y et al. Inhibition of Kv1.3 potassium current by phosphoinositides and stromal-derived factor-1alpha in Jurkat T cells.
Am. J. Physiol., Cell Physiol., 2009 May , 296 (C1079-85).

283

Nekrasova OV et al. Recombinant Kv channels at the membrane of Escherichia coli bind specifically agitoxin2.
J Neuroimmune Pharmacol, 2009 Mar , 4 (83-91).

284

Gendelman HE et al. Monocyte chemotactic protein-1 regulates voltage-gated K+ channels and macrophage transmigration.
J Neuroimmune Pharmacol, 2009 Mar , 4 (47-59).

285

Kawano T et al. Globotriaosylceramide-expressing Burkitt's lymphoma cells are committed to early apoptotic status by rhamnose-binding lectin from catfish eggs.
Biol. Pharm. Bull., 2009 Mar , 32 (345-53).

286

Teisseyre A et al. Influence of the multidrug transporter inhibitors on the activity of Kv1.3 voltage-gated potassium channels.
J. Physiol. Pharmacol., 2009 Mar , 60 (69-76).

287

Toth A et al. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse.
Immunol. Lett., 2009 Jun 30 , 125 (15-21).

288

Peitz I et al. Electrical interfacing of neurotransmitter receptor and field effect transistor.
, 2009 Jun 10 , ().

289

Bittner S et al. Comment on "Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse"
Immunol. Lett., 2009 Jul 9 , ().

290

Ader C et al. Protein dynamics detected in a membrane-embedded potassium channel using two-dimensional solid-state NMR spectroscopy.
Biochim. Biophys. Acta, 2009 Jul 10 , ().

291

Winklmeier A et al. Crystallization and preliminary X-ray diffraction studies of the tetramerization domain derived from the human potassium channel Kv1.3.
Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2009 Jul 1 , 65 (688-91).

292

Kuras Z et al. Effect of K+ and Rb+ on the action of verapamil on a voltage-gated K+ channel, hKv1.3: implications for a second open state?
Br. J. Pharmacol., 2009 Jul , 157 (757-68).

293

Feng DY et al. [Kv1.3 potassium channel expression changes after CD4(+) and subsets CD28(null)/CD28(+)T cells activation in peripheral blood of patients with acute coronary syndrome]
Zhonghua Xin Xue Guan Bing Za Zhi, 2009 Jul , 37 (599-604).

294

Ader C et al. Structural rearrangements of membrane proteins probed by water-edited solid-state NMR spectroscopy.
J. Am. Chem. Soc., 2009 Jan 14 , 131 (170-6).

295

Satuluri VS et al. A quantitative structure-activity relationship study on some series of potassium channel blockers.
, 2009 Jan , 5 (87-92).

296

Li MW et al. [Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes]
Zhonghua Xin Xue Guan Bing Za Zhi, 2009 Feb , 37 (165-8).

297

Szewczyk A et al. Mitochondrial potassium channels.
IUBMB Life, 2009 Feb , 61 (134-43).

298

Takacs Z et al. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
Proc. Natl. Acad. Sci. U.S.A., 2009 Dec 29 , 106 (22211-6).

299

Valencia-Cruz G et al. K(bg) and Kv1.3 channels mediate potassium efflux in the early phase of apoptosis in Jurkat T lymphocytes.
Am. J. Physiol., Cell Physiol., 2009 Dec , 297 (C1544-53).

300

Bielanska J et al. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer.
Curr Cancer Drug Targets, 2009 Dec , 9 (904-14).

301

Ader C et al. Coupling of activation and inactivation gate in a K(+)-channel: potassium and ligand sensitivity.
EMBO J., 2009 Aug 6 , ().

302

Jang SH et al. Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer.
BMB Rep, 2009 Aug 31 , 42 (535-9).

303

Brevet M et al. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation.
Pancreas, 2009 Aug , 38 (649-54).

304

Rangaraju S et al. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Expert Opin. Ther. Targets, 2009 Aug , 13 (909-24).

305

Pegoraro S et al. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
Bioorg. Med. Chem. Lett., 2009 Apr 15 , 19 (2299-304).

306

Pennington MW et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Mol. Pharmacol., 2009 Apr , 75 (762-73).

307

Liu J et al. Molecular cloning and functional identification of a new K(+) channel blocker, LmKTx10, from the scorpion Lychas mucronatus.
Peptides, 2009 Apr , 30 (675-80).

308

Colley BS et al. Brain-derived neurotrophic factor modulation of Kv1.3 channel is disregulated by adaptor proteins Grb10 and nShc.
, 2009 , 10 (8).

309

Oguchi T et al. Enantioselective total synthesis of (-)-candelalides A, B and C: potential Kv1.3 blocking immunosuppressive agents.
, 2009 , 15 (2826-45).

310

Bednarczyk P Potassium channels in brain mitochondria.
Acta Biochim. Pol., 2009 , 56 (385-92).

311

Laufer J et al. The C-terminal PDZ-binding motif in the Kv1.5 potassium channel governs its modulation by the Na+/H+ exchanger regulatory factor 2.
Cell. Physiol. Biochem., 2009 , 23 (25-36).

312

Xuan NT et al. Ca2+-dependent functions in peptidoglycan-stimulated mouse dendritic cells.
Cell. Physiol. Biochem., 2009 , 24 (167-76).

313

Moussaud S et al. Characterisation of K+ currents in the C8-B4 microglial cell line and their regulation by microglia activating stimuli.
Cell. Physiol. Biochem., 2009 , 24 (141-52).

314

Menteyne A et al. Predominant functional expression of Kv1.3 by activated microglia of the hippocampus after Status epilepticus.
PLoS ONE, 2009 , 4 (e6770).

315

Szabò I et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes.
Proc. Natl. Acad. Sci. U.S.A., 2008 Sep 30 , 105 (14861-6).

316

Matsushita Y et al. Molecular mechanisms for Kv1.3 potassium channel current inhibition by CD3/CD28 stimulation in Jurkat T cells.
Biochem. Biophys. Res. Commun., 2008 Sep 12 , 374 (152-7).

317

Somodi S et al. Effects of changes in extracellular pH and potassium concentration on Kv1.3 inactivation.
Eur. Biophys. J., 2008 Sep , 37 (1145-56).

318

Pottosin II et al. TRESK-like potassium channels in leukemic T cells.
Pflugers Arch., 2008 Sep , 456 (1037-48).

319

Shijin Y et al. Characterization of a new Kv1.3 channel-specific blocker, J123, from the scorpion Buthus martensii Karsch.
Peptides, 2008 Sep , 29 (1514-20).

320

De Simoni A et al. Charge compensation for NADPH oxidase activity in microglia in rat brain slices does not involve a proton current.
Eur. J. Neurosci., 2008 Sep , 28 (1146-56).

321

Doczi MA et al. Kv1.3 channels in postganglionic sympathetic neurons: expression, function, and modulation.
Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008 Sep , 295 (R733-40).

322

Corzo G et al. A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus.
Biochem. Pharmacol., 2008 Oct 30 , 76 (1142-54).

323

Matheu MP et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Immunity, 2008 Oct 17 , 29 (602-14).

324

Abbas N et al. A new Kaliotoxin selective towards Kv1.3 and Kv1.2 but not Kv1.1 channels expressed in oocytes.
Biochem. Biophys. Res. Commun., 2008 Nov 21 , 376 (525-30).

325

Li YF et al. Voltage-gated potassium channel Kv1.3 in rabbit ciliary epithelium regulates the membrane potential via coupling intracellular calcium.
Chin. Med. J., 2008 Nov 20 , 121 (2272-7).

326

Matzner N et al. Ion channels modulating mouse dendritic cell functions.
J. Immunol., 2008 Nov 15 , 181 (6803-9).

327

Yin SJ et al. Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels.
J. Proteome Res., 2008 Nov , 7 (4890-7).

328

Zarrabi M et al. The investigation of interactions of kappa-Hefutoxin1 with the voltage-gated potassium channels: a computational simulation.
Proteins, 2008 May 15 , 71 (1441-9).

329

Estes DJ et al. High-throughput profiling of ion channel activity in primary human lymphocytes.
Anal. Chem., 2008 May 15 , 80 (3728-35).

330

Villalonga N et al. Cell cycle-dependent expression of Kv1.5 is involved in myoblast proliferation.
Biochim. Biophys. Acta, 2008 May , 1783 (728-36).

331

Millar ID et al. Kv1 and Kir2 potassium channels are expressed in rat brain endothelial cells.
Pflugers Arch., 2008 May , 456 (379-91).

332

Zachariae U et al. The molecular mechanism of toxin-induced conformational changes in a potassium channel: relation to C-type inactivation.
Structure, 2008 May , 16 (747-54).

333

Poulopoulou C et al. Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus.
Arthritis Rheum., 2008 May , 58 (1445-50).

334

Vicente R et al. Kv1.5 association modifies Kv1.3 traffic and membrane localization.
J. Biol. Chem., 2008 Mar 28 , 283 (8756-64).

335

Cianci J et al. Synthesis and biological evaluation of chalcones as inhibitors of the voltage-gated potassium channel Kv1.3.
Bioorg. Med. Chem. Lett., 2008 Mar 15 , 18 (2055-61).

336

Utsunomiya I et al. Expression and localization of Kv1 potassium channels in rat dorsal and ventral spinal roots.
Exp. Neurol., 2008 Mar , 210 (51-8).

337

Abdel-Mottaleb Y et al. OdK2, a Kv1.3 channel-selective toxin from the venom of the Iranian scorpion Odonthobuthus doriae.
Toxicon, 2008 Jun 15 , 51 (1424-30).

338

Schneider R et al. Solid-state NMR spectroscopy applied to a chimeric potassium channel in lipid bilayers.
J. Am. Chem. Soc., 2008 Jun 11 , 130 (7427-35).

339

Ader C et al. A structural link between inactivation and block of a K+ channel.
Nat. Struct. Mol. Biol., 2008 Jun , 15 (605-12).

340

Han S et al. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
J. Biol. Chem., 2008 Jul 4 , 283 (19058-65).

341

Ren XT et al. [Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4+ T lymphocytes in multiple sclerosis]
Zhonghua Yi Xue Za Zhi, 2008 Jul 15 , 88 (1896-9).

342

Huang S et al. [Upregulated voltage-gated potassium channel Kv1.3 on the CD4+CD28null T lymphocyte from patients with acute coronary syndrome]
Zhonghua Xin Xue Guan Bing Za Zhi, 2008 Jul , 36 (602-7).

343

Beeton C et al. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
J. Biol. Chem., 2008 Jan 11 , 283 (988-97).

344

Biju KC et al. Deletion of voltage-gated channel affects glomerular refinement and odorant receptor expression in the mouse olfactory system.
J. Comp. Neurol., 2008 Jan 10 , 506 (161-79).

345

Petroff EY et al. Acid-sensing ion channels interact with and inhibit BK K+ channels.
Proc. Natl. Acad. Sci. U.S.A., 2008 Feb 26 , 105 (3140-4).

346

Salom JB et al. Role of K+ and Ca2+ fluxes in the cerebroarterial vasoactive effects of sildenafil.
Eur. J. Pharmacol., 2008 Feb 26 , 581 (138-47).

347

Yankelson L et al. Cell therapy for modification of the myocardial electrophysiological substrate.
Circulation, 2008 Feb 12 , 117 (720-31).

348

Franco R et al. Glutathione depletion and disruption of intracellular ionic homeostasis regulate lymphoid cell apoptosis.
J. Biol. Chem., 2008 Dec 26 , 283 (36071-87).

349

Liang ZT et al. High extracellular potassium ion concentration attenuates the blockade action of ketanserin on Kv1.3 channels expressed in xenopus oocytes.
Chin. Med. J., 2008 Dec 20 , 121 (2584-91).

350

Martínez-Mármol R et al. Multiple Kv1.5 targeting to membrane surface microdomains.
J. Cell. Physiol., 2008 Dec , 217 (667-73).

351

Cui JX et al. [Study on the roles of voltaged potassium channels in acute hypoxic pulmonary vasoconstriction]
Nan Fang Yi Ke Da Xue Xue Bao, 2008 Dec , 28 (2200-1).

352

Tucker K et al. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice.
, 2008 Aug , 32 (1222-32).

353

Mello de Queiroz F et al. Study of membrane potential in T lymphocytes subpopulations using flow cytometry.
BMC Immunol., 2008 , 9 (63).

354

Hu X et al. Kv1.3 channel as a promising therapeutic target for acquired aplastic anemia.
Med. Hypotheses, 2008 , 70 (1072).

355

Ren YR et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes.
PLoS ONE, 2008 , 3 (e4009).

356

Jin L et al. Molecular mechanism of the sea anemone toxin ShK recognizing the Kv1.3 channel explored by docking and molecular dynamic simulations.
, 2007 Sep-Oct , 47 (1967-72).

357

Mao X et al. Cloning and characterization of BmK86, a novel K+ -channel blocker from scorpion venom.
Biochem. Biophys. Res. Commun., 2007 Sep 7 , 360 (728-34).

358

Guo LF et al. [T-lymphocyte voltage dependent K(+) channel is upregulated in patients with acute coronary syndrome]
Zhonghua Xin Xue Guan Bing Za Zhi, 2007 Sep , 35 (818-21).

359

Wang J et al. An intermediate-conductance Ca(2+)-activated K (+) channel mediates B lymphoma cell cycle progression induced by serum.
Pflugers Arch., 2007 Sep , 454 (945-56).

360

Hu L et al. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
J. Immunol., 2007 Oct 1 , 179 (4563-70).

361

Derfuss T et al. Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia.
Brain Pathol., 2007 Oct , 17 (389-98).

362

Zahn PK et al. Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: a pertussis toxin-sensitive G protein-dependent process.
Anesthesiology, 2007 Nov , 107 (797-806).

363

Pereira LE et al. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.
Exp. Biol. Med. (Maywood), 2007 Nov , 232 (1338-54).

364

Marks DR et al. Post-synaptic density perturbs insulin-induced Kv1.3 channel modulation via a clustering mechanism involving the SH3 domain.
J. Neurochem., 2007 Nov , 103 (1608-27).

365

Kim SE et al. Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine.
J. Pharmacol. Exp. Ther., 2007 May , 321 (753-62).

366

Ahn HS et al. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property.
Am. J. Physiol., Cell Physiol., 2007 May , 292 (C1714-22).

367

Pottosin II et al. Methyl-beta-cyclodextrin reversibly alters the gating of lipid rafts-associated Kv1.3 channels in Jurkat T lymphocytes.
Pflugers Arch., 2007 May , 454 (235-44).

368

Buraei Z et al. Roscovitine differentially affects CaV2 and Kv channels by binding to the open state.
Neuropharmacology, 2007 Mar , 52 (883-94).

369

Kim DS et al. Seizure activity affects neuroglial Kv1 channel immunoreactivities in the gerbil hippocampus.
Brain Res., 2007 Jun 2 , 1151 (172-87).

370

Azam P et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.
J. Invest. Dermatol., 2007 Jun , 127 (1419-29).

371

Gill S et al. A cell-based Rb(+)-flux assay of the Kv1.3 potassium channel.
, 2007 Jun , 5 (373-80).

372

Shoudai K et al. Effects of various K+ channel blockers on spontaneous glycine release at rat spinal neurons.
Brain Res., 2007 Jul 9 , 1157 (11-22).

373

Tu L et al. Biogenesis of the T1-S1 linker of voltage-gated K+ channels.
Biochemistry, 2007 Jul 10 , 46 (8075-84).

374

Nicolaou SA et al. Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus.
J. Immunol., 2007 Jul 1 , 179 (346-56).

375

Wulff H et al. Targeting effector memory T-cells with Kv1.3 blockers.
, 2007 Jul , 10 (438-45).

376

Villalonga N et al. Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages.
Biochem. Biophys. Res. Commun., 2007 Jan 26 , 352 (913-8).

377

Colley BS et al. Neurotrophin B receptor kinase increases Kv subfamily member 1.3 (Kv1.3) ion channel half-life and surface expression.
Neuroscience, 2007 Jan 19 , 144 (531-46).

378

Ahn HS et al. Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.
Naunyn Schmiedebergs Arch. Pharmacol., 2007 Jan , 374 (305-9).

379

Rivera J et al. The role of Kif5B in axonal localization of Kv1 K(+) channels.
Eur. J. Neurosci., 2007 Jan , 25 (136-46).

380

Ousingsawat J et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma.
Clin. Cancer Res., 2007 Feb 1 , 13 (824-31).

381

Helyer R et al. A model for mammalian cochlear hair cell differentiation in vitro: effects of retinoic acid on cytoskeletal proteins and potassium conductances.
Eur. J. Neurosci., 2007 Feb , 25 (957-73).

382

Moritoki Y et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers.
Hepatology, 2007 Feb , 45 (314-22).

383

Tang Q et al. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Biochem. Pharmacol., 2007 Dec 3 , 74 (1596-607).

384

Wu W et al. Molecular cloning and electrophysiological studies on the first K(+) channel toxin (LmKTx8) derived from scorpion Lychas mucronatus.
Peptides, 2007 Dec , 28 (2306-12).

385

Nutile-McMenemy N et al. Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression.
J. Neurochem., 2007 Dec , 103 (2035-46).

386

Teisseyre A et al. The modulatory effect of zinc ions on voltage-gated potassium currents in cultured rat hippocampal neurons is not related to Kv1.3 channels.
J. Physiol. Pharmacol., 2007 Dec , 58 (699-715).

387

Wang X et al. Blockade action of ketanserin and increasing effect of potassium ion on Kv1.3 channels expressed in Xenopus oocytes.
Pharmacol. Res., 2007 Aug , 56 (148-54).

388

Few WP et al. Sex differences in and hormonal regulation of Kv1 potassium channel gene expression in the electric organ: molecular control of a social signal.
Dev Neurobiol, 2007 Apr , 67 (535-49).

389

Bruhova I et al. Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions.
BMC Struct. Biol., 2007 , 7 (5).

390

Teisseyre A et al. The influence of protons and zinc ions on the steady-state inactivation of Kv1.3 potassium channels.
Cell. Mol. Biol. Lett., 2007 , 12 (220-30).

391

Székely A et al. Nutrition and immune system: certain fatty acids differently modify membrane composition and consequently kinetics of KV1.3 channels of human peripheral lymphocytes.
Immunobiology, 2007 , 212 (213-27).

392

Hoegg S et al. Phylogenomic analyses of KCNA gene clusters in vertebrates: why do gene clusters stay intact?
BMC Evol. Biol., 2007 , 7 (139).

393

Decher N et al. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
Mol. Pharmacol., 2006 Oct , 70 (1204-11).

394

Lang F et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms.
Physiol. Rev., 2006 Oct , 86 (1151-78).

395

Liebau S et al. Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation.
J. Neurochem., 2006 Oct , 99 (426-37).

396

Beeton C et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Proc. Natl. Acad. Sci. U.S.A., 2006 Nov 14 , 103 (17414-9).

397

Novakovic A et al. The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery.
J. Pharmacol. Sci., 2006 May , 101 (85-90).

398

Teisseyre A et al. Influence of extracellular pH on the modulatory effect of zinc ions on Kv1.3 potassium channels.
J. Physiol. Pharmacol., 2006 Mar , 57 (131-47).

399

Wollmann G et al. Voltage-dependent ion channels in the mouse RPE: comparison with Norrie disease mice.
Vision Res., 2006 Mar , 46 (688-98).

400

Detre C et al. Death or survival: membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration.
Cell. Signal., 2006 Mar , 18 (294-306).

401

Lei XJ et al. Inhibitory effects of blocking voltage-dependent potassium channel 1.3 on human monocyte-derived macrophage differentiation into foam cells.
Beijing Da Xue Xue Bao, 2006 Jun 18 , 38 (257-61).

402

Szigligeti P et al. Signalling during hypoxia in human T lymphocytes--critical role of the src protein tyrosine kinase p56Lck in the O2 sensitivity of Kv1.3 channels.
J. Physiol. (Lond.), 2006 Jun 1 , 573 (357-70).

403

Teisseyre A et al. The inhibitory effect of copper ions on lymphocyte Kv1.3 potassium channels.
J. Physiol. Pharmacol., 2006 Jun , 57 (301-14).

404

Mullen KM et al. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system.
Ann. Neurol., 2006 Jul , 60 (118-27).

405

Abdel-Mottaleb Y et al. A novel toxin from the venom of the scorpion Tityus trivittatus, is the first member of a new alpha-KTX subfamily.
FEBS Lett., 2006 Jan 23 , 580 (592-6).

406

Liang CZ et al. K channel expression in prostate epithelium and its implications in men with chronic prostatitis.
BJU Int., 2006 Jan , 97 (190-2).

407

Harvey AJ et al. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
J. Med. Chem., 2006 Feb 23 , 49 (1433-41).

408

Slack M et al. Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
, 2006 Feb , 11 (57-64).

409

Li Y et al. Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism.
Am. J. Physiol., Cell Physiol., 2006 Feb , 290 (C345-51).

410

Tschritter O et al. A new variant in the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance.
J. Clin. Endocrinol. Metab., 2006 Feb , 91 (654-8).

411

Vicente R et al. Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages.
J. Biol. Chem., 2006 Dec 8 , 281 (37675-85).

412

Wang F et al. Structural and functional analysis of natrin, a venom protein that targets various ion channels.
Biochem. Biophys. Res. Commun., 2006 Dec 15 , 351 (443-8).

413

Pannasch U et al. The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia.
Mol. Cell. Neurosci., 2006 Dec , 33 (401-11).

414

Lei XJ et al. [Inhibition of human macrophage-derived foam cell differentiation by blocking Kv1.3 and Kir2.1 channels]
Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2006 Aug , 31 (493-8).

415

Vámosi G et al. The role of supramolecular protein complexes and membrane potential in transmembrane signaling processes of lymphocytes.
Immunol. Lett., 2006 Apr 15 , 104 (53-8).

416

Lange A et al. Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR.
Nature, 2006 Apr 13 , 440 (959-62).

417

Rossokhin A et al. Interaction of d-tubocurarine with potassium channels: molecular modeling and ligand binding.
Mol. Pharmacol., 2006 Apr , 69 (1356-65).

418

Abdul M et al. Reduced Kv1.3 potassium channel expression in human prostate cancer.
J. Membr. Biol., 2006 , 214 (99-102).

419

Lange A et al. Two-dimensional solid-state NMR applied to a chimeric potassium channel.
J. Recept. Signal Transduct. Res., 2006 , 26 (379-93).

420

Panyi G et al. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.
Curr. Pharm. Des., 2006 , 12 (2199-220).

421

Lawson K et al. Modulation of potassium channels as a therapeutic approach.
Curr. Pharm. Des., 2006 , 12 (459-70).

422

Teisseyre A et al. Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol.
J. Membr. Biol., 2006 , 214 (123-9).

423

Feske S et al. A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients.
J. Exp. Med., 2005 Sep 5 , 202 (651-62).

424

Olamendi-Portugal T et al. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K+ channels of T cells.
Toxicon, 2005 Sep 15 , 46 (418-29).

425

Newell EW et al. Integration of K+ and Cl- currents regulate steady-state and dynamic membrane potentials in cultured rat microglia.
J. Physiol. (Lond.), 2005 Sep 15 , 567 (869-90).

426

Das P et al. Electrophysiological and behavioral phenotype of insulin receptor defective mice.
Physiol. Behav., 2005 Oct 15 , 86 (287-96).

427

Dreker T et al. Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.
Mol. Pharmacol., 2005 Oct , 68 (966-73).

428

Rivera JF et al. The T1 domain of Kv1.3 mediates intracellular targeting to axons.
Eur. J. Neurosci., 2005 Oct , 22 (1853-62).

429

Chagot B et al. An unusual fold for potassium channel blockers: NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis.
Biochem. J., 2005 May 15 , 388 (263-71).

430

O'Connell KM et al. Targeting of voltage-gated potassium channel isoforms to distinct cell surface microdomains.
J. Cell. Sci., 2005 May 15 , 118 (2155-66).

431

Yan L et al. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels.
Mol. Pharmacol., 2005 May , 67 (1513-21).

432

Teisseyre A et al. Genistein inhibits the activity of kv1.3 potassium channels in human T lymphocytes.
J. Membr. Biol., 2005 May , 205 (71-9).

433

Poulopoulou C et al. Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate.
Mol. Pharmacol., 2005 Mar , 67 (856-67).

434

Bode CW et al. 5-(3-Phenylpropoxy)psoralen and 5-(4-phenylbutoxy)psoralen: mechanistic studies on phototoxicity.
Pharmazie, 2005 Mar , 60 (225-8).

435

Lu J et al. Secondary structure formation of a transmembrane segment in Kv channels.
Biochemistry, 2005 Jun 14 , 44 (8230-43).

436

Srairi-Abid N et al. A new type of scorpion Na+-channel-toxin-like polypeptide active on K+ channels.
Biochem. J., 2005 Jun 1 , 388 (455-64).

437

Valverde P et al. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
J. Dent. Res., 2005 Jun , 84 (488-99).

438

Desir GV Kv1.3 potassium channel blockade as an approach to insulin resistance.
Expert Opin. Ther. Targets, 2005 Jun , 9 (571-9).

439

Heusser K et al. Trafficking of potassium channels.
Curr. Opin. Neurobiol., 2005 Jun , 15 (364-9).

440

Krasnowska M et al. [The conductivity of potassium ion channels in lymphocytes T of patients with pollinosis]
Pol. Merkur. Lekarski, 2005 Jun , 18 (617-9).

441

Harvey AJ et al. A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.
Bioorg. Med. Chem. Lett., 2005 Jul 1 , 15 (3193-6).

442

Bao J et al. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bioorg. Med. Chem. Lett., 2005 Jan 17 , 15 (447-51).

443

McCloskey KD Characterization of outward currents in interstitial cells from the guinea pig bladder.
J. Urol., 2005 Jan , 173 (296-301).

444

Vallon V et al. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure.
Curr. Opin. Nephrol. Hypertens., 2005 Jan , 14 (59-66).

445

Chung YH et al. Immunohistochemical study on the distribution of the voltage-gated potassium channels in the gerbil cerebellum.
Neurosci. Lett., 2005 Feb 1 , 374 (58-62).

446

Liu HL et al. Homology models of the tetramerization domain of six eukaryotic voltage-gated potassium channels Kv1.1-Kv1.6.
J. Biomol. Struct. Dyn., 2005 Feb , 22 (387-98).

447

Beeton C et al. Potassium channels, memory T cells, and multiple sclerosis.
, 2005 Dec , 11 (550-62).

448

Lan M et al. Expression of delayed rectifier potassium channels and their possible roles in proliferation of human gastric cancer cells.
Cancer Biol. Ther., 2005 Dec , 4 (1342-7).

449

Fordyce CB et al. Microglia Kv1.3 channels contribute to their ability to kill neurons.
J. Neurosci., 2005 Aug 3 , 25 (7139-49).

450

Rus H et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.
Proc. Natl. Acad. Sci. U.S.A., 2005 Aug 2 , 102 (11094-9).

451

Watanabe K et al. Enantioselective total synthesis of (-)-candelalide A, a novel blocker of the voltage-gated potassium channel Kv1.3 for an immunosuppressive agent.
Org. Lett., 2005 Aug 18 , 7 (3745-8).

452

Vicente R et al. Pattern of Kv beta subunit expression in macrophages depends upon proliferation and the mode of activation.
J. Immunol., 2005 Apr 15 , 174 (4736-44).

453

Szabò I et al. A novel potassium channel in lymphocyte mitochondria.
J. Biol. Chem., 2005 Apr 1 , 280 (12790-8).

454

Robbins JR et al. Hypoxia modulates early events in T cell receptor-mediated activation in human T lymphocytes via Kv1.3 channels.
J. Physiol. (Lond.), 2005 Apr 1 , 564 (131-43).

455

Bagdány M et al. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Mol. Pharmacol., 2005 Apr , 67 (1034-44).

456

Beeton C et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Mol. Pharmacol., 2005 Apr , 67 (1369-81).

457

Strauss U et al. Dopamine exerts no acute effects on Kv1.3 in activated encephalitogenic T cells.
Neuroimmunomodulation, 2005 , 12 (45-53).

458

Persson AS et al. A truncated Kv1.1 protein in the brain of the megencephaly mouse: expression and interaction.
, 2005 , 6 (65).

459

Lang F et al. Cell volume and the regulation of apoptotic cell death.
J. Mol. Recognit., 2004 Sep-Oct , 17 (473-80).

460

Bähring R et al. Differential modulation of Kv1 channel-mediated currents by co-expression of Kvbeta3 subunit in a mammalian cell-line.
Mol. Membr. Biol., 2004 Jan-Feb , 21 (19-25).

461

Wang W Renal potassium channels: recent developments.
Curr. Opin. Nephrol. Hypertens., 2004 Sep , 13 (549-55).

462

Kosolapov A et al. Structure acquisition of the T1 domain of Kv1.3 during biogenesis.
Neuron, 2004 Oct 14 , 44 (295-307).

463

Damjanovich S et al. An alternative to conventional immunosuppression: small-molecule inhibitors of Kv1.3 channels.
Mol. Interv., 2004 Oct , 4 (250-4).

464

Kauferstein S et al. Novel conopeptides of the I-superfamily occur in several clades of cone snails.
Toxicon, 2004 Oct , 44 (539-48).

465

Yamaji N et al. Solution structure of IsTX. A male scorpion toxin from Opisthacanthus madagascariensis (Ischnuridae).
Eur. J. Biochem., 2004 Oct , 271 (3855-64).

466

Teisseyre A et al. The influence of zinc on the modulatory effect of sphingosylphosphorylcholine on Kv1.3 channels in human T lymphocytes.
Eur. Biophys. J., 2004 Oct , 33 (543-8).

467

Somodi S et al. pH-dependent modulation of Kv1.3 inactivation: role of His399.
Am. J. Physiol., Cell Physiol., 2004 Oct , 287 (C1067-76).

468

Visan V et al. Mapping of maurotoxin binding sites on hKv1.2, hKv1.3, and hIKCa1 channels.
Mol. Pharmacol., 2004 Nov , 66 (1103-12).

469

Henke G et al. Regulation of the voltage gated K+ channel Kv1.3 by the ubiquitin ligase Nedd4-2 and the serum and glucocorticoid inducible kinase SGK1.
J. Cell. Physiol., 2004 May , 199 (194-9).

470

Chandy KG et al. K+ channels as targets for specific immunomodulation.
Trends Pharmacol. Sci., 2004 May , 25 (280-9).

471

Devaux J et al. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers]
Rev. Neurol. (Paris), 2004 May , 160 (S16-27).

472

Panyi G et al. Ion channels and lymphocyte activation.
Immunol. Lett., 2004 Mar 29 , 92 (55-66).

473

Xu J et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity.
Proc. Natl. Acad. Sci. U.S.A., 2004 Mar 2 , 101 (3112-7).

474

Speake T et al. Kv1.1 and Kv1.3 channels contribute to the delayed-rectifying K+ conductance in rat choroid plexus epithelial cells.
Am. J. Physiol., Cell Physiol., 2004 Mar , 286 (C611-20).

475

Jäger H et al. Characterization of the outer pore region of the apamin-sensitive Ca2+-activated K+ channel rSK2.
Toxicon, 2004 Jun 15 , 43 (951-60).

476

Ferber M et al. Identification of a mammalian target of kappaM-conotoxin RIIIK.
Toxicon, 2004 Jun 15 , 43 (915-21).

477

Ebbinghaus J et al. Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi.
Toxicon, 2004 Jun 15 , 43 (923-32).

478

Zhang N et al. Solution structure of BmKK2, a new potassium channel blocker from the venom of chinese scorpion Buthus martensi Karsch.
Proteins, 2004 Jun 1 , 55 (835-45).

479

Vennekamp J et al. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Mol. Pharmacol., 2004 Jun , 65 (1364-74).

480

Szabò I et al. Ion channels and membrane rafts in apoptosis.
Pflugers Arch., 2004 Jun , 448 (304-12).

481

Yu K et al. Computational simulations of interactions of scorpion toxins with the voltage-gated potassium ion channel.
Biophys. J., 2004 Jun , 86 (3542-55).

482

Wulff H et al. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.
J. Immunol., 2004 Jul 15 , 173 (776-86).

483

Huys I et al. A subfamily of acidic alpha-K(+) toxins.
J. Biol. Chem., 2004 Jan 23 , 279 (2781-9).

484

Mouhat S et al. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
Biochem. J., 2004 Jan 1 , 377 (25-36).

485

Valverde P et al. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease.
J. Bone Miner. Res., 2004 Jan , 19 (155-64).

486

Duzhyy DE et al. Cloning and developmental expression of Shaker potassium channels in the cochlea of the chicken.
Brain Res. Mol. Brain Res., 2004 Feb 5 , 121 (70-85).

487

Fadool DA et al. Kv1.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics.
Neuron, 2004 Feb 5 , 41 (389-404).

488

Panyi G et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells.
Proc. Natl. Acad. Sci. U.S.A., 2004 Feb 3 , 101 (1285-90).

489

Regaya I et al. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins.
J. Biol. Chem., 2004 Dec 31 , 279 (55690-6).

490

Vautier F et al. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation.
Glia, 2004 Dec , 48 (337-45).

491

Vicente R et al. The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways.
FEBS Lett., 2004 Aug 13 , 572 (189-94).

492

Xu CQ et al. BmBKTx1, a novel Ca2+-activated K+ channel blocker purified from the Asian scorpion Buthus martensi Karsch.
J. Biol. Chem., 2004 Aug 13 , 279 (34562-9).

493

Baell JB et al. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
J. Med. Chem., 2004 Apr 22 , 47 (2326-36).

494

Huys I et al. Structure-function study of a chlorotoxin-chimer and its activity on Kv1.3 channels.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004 Apr 15 , 803 (67-73).

495

Escobar LI et al. A voltage-gated K(+) current in renal inner medullary collecting duct cells.
Am. J. Physiol., Cell Physiol., 2004 Apr , 286 (C965-74).

496

Wernekenschnieder A et al. 3-Alkyl- and 3-aryl-7H-furo[3,2-g]chromen-7-ones as blockers of the voltage-gated potassium channel Kv1.3.
Pharmazie, 2004 Apr , 59 (319-20).

497

Mahjoubi-Boubaker B et al. Kbot1, a three disulfide bridges toxin from Buthus occitanus tunetanus venom highly active on both SK and Kv channels.
Peptides, 2004 Apr , 25 (637-45).

498

Colley B et al. Comparison of modulation of Kv1.3 channel by two receptor tyrosine kinases in olfactory bulb neurons of rodents.
Recept. Channels, 2004 , 10 (25-36).

499

Yang EK et al. Altered expression of potassium channel subunit mRNA and alpha-dendrotoxin sensitivity of potassium currents in rat dorsal root ganglion neurons after axotomy.
Neuroscience, 2004 , 123 (867-74).

500

Vianna-Jorge R et al. Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?
, 2004 , 18 (329-41).

501

Abdul M et al. Activity of potassium channel-blockers in breast cancer.
Anticancer Res., 2003 Jul-Aug , 23 (3347-51).

502

Grunnet M et al. The voltage-gated potassium channel subunit, Kv1.3, is expressed in epithelia.
Biochim. Biophys. Acta, 2003 Sep 22 , 1616 (85-94).

503

Wulff H et al. Potassium channels as therapeutic targets for autoimmune disorders.
, 2003 Sep , 6 (640-7).

504

Grunnet M et al. KCNE4 is an inhibitory subunit to Kv1.1 and Kv1.3 potassium channels.
Biophys. J., 2003 Sep , 85 (1525-37).

505

M'Barek S et al. Synthesis and characterization of Pi4, a scorpion toxin from Pandinus imperator that acts on K+ channels.
Eur. J. Biochem., 2003 Sep , 270 (3583-92).

506

Koni PA et al. Compensatory anion currents in Kv1.3 channel-deficient thymocytes.
J. Biol. Chem., 2003 Oct 10 , 278 (39443-51).

507

MacKenzie AB et al. Kv1.3 potassium channels in human alveolar macrophages.
Am. J. Physiol. Lung Cell Mol. Physiol., 2003 Oct , 285 (L862-8).

508

Vicente R et al. Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages.
J. Biol. Chem., 2003 Nov 21 , 278 (46307-20).

509

Lampert A et al. Effect of dexamethasone on voltage-gated K+ channels in Jurkat T-lymphocytes.
Pflugers Arch., 2003 Nov , 447 (168-74).

510

Huys I et al. Evidence for a function-specific mutation in the neurotoxin, parabutoxin 3.
Eur. J. Neurosci., 2003 May , 17 (1786-92).

511

Panyi G et al. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes.
Proc. Natl. Acad. Sci. U.S.A., 2003 Mar 4 , 100 (2592-7).

512

Miao S et al. Benzamide derivatives as blockers of Kv1.3 ion channel.
Bioorg. Med. Chem. Lett., 2003 Mar 24 , 13 (1161-4).

513

Beeton C et al. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
J. Biol. Chem., 2003 Mar 14 , 278 (9928-37).

514

Xu J et al. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight.
Hum. Mol. Genet., 2003 Mar 1 , 12 (551-9).

515

Rivera JF et al. An evolutionarily conserved dileucine motif in Shal K+ channels mediates dendritic targeting.
Nat. Neurosci., 2003 Mar , 6 (243-50).

516

Hajdu P et al. Cholesterol modifies the gating of Kv1.3 in human T lymphocytes.
Pflugers Arch., 2003 Mar , 445 (674-82).

517

Bock J et al. Ceramide inhibits the potassium channel Kv1.3 by the formation of membrane platforms.
Biochem. Biophys. Res. Commun., 2003 Jun 13 , 305 (890-7).

518

Wulff H et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
J. Clin. Invest., 2003 Jun , 111 (1703-13).

519

Lee SY et al. Adult alveolar epithelial cells express multiple subtypes of voltage-gated K+ channels that are located in apical membrane.
Am. J. Physiol., Cell Physiol., 2003 Jun , 284 (C1614-24).

520

Preussat K et al. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas.
Neurosci. Lett., 2003 Jul 31 , 346 (33-6).

521

Kauferstein S et al. A novel conotoxin inhibiting vertebrate voltage-sensitive potassium channels.
Toxicon, 2003 Jul , 42 (43-52).

522

Rodrigues AR et al. Tityustoxin-K(alpha) blockade of the voltage-gated potassium channel Kv1.3.
Br. J. Pharmacol., 2003 Jul , 139 (1180-6).

523

Conforti L et al. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation.
J. Immunol., 2003 Jan 15 , 170 (695-702).

524

Vianna-Jorge R et al. Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea-pig ileum by stimulating acetylcholine and tachykinins release by the enteric nervous system.
Br. J. Pharmacol., 2003 Jan , 138 (57-62).

525

Teisseyre A et al. The voltage- and time-dependent blocking effect of trifluoperazine on T lymphocyte Kv1.3 channels.
Biochem. Pharmacol., 2003 Feb 15 , 65 (551-61).

526

Peukert S et al. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
J. Med. Chem., 2003 Feb 13 , 46 (486-98).

527

Coma M et al. Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia.
FEBS Lett., 2003 Feb 11 , 536 (45-50).

528

Castle NA et al. Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels.
Mol. Pharmacol., 2003 Feb , 63 (409-18).

529

Shah K et al. Immunosuppressive effects of a Kv1.3 inhibitor.
Cell. Immunol., 2003 Feb , 221 (100-6).

530

Schilling T et al. Effects of kinase inhibitors on TGF-beta induced upregulation of Kv1.3 K+ channels in brain macrophages.
Pflugers Arch., 2003 Dec , 447 (312-5).

531

Petersson S et al. Truncation of the Shaker-like voltage-gated potassium channel, Kv1.1, causes megencephaly.
Eur. J. Neurosci., 2003 Dec , 18 (3231-40).

532

Storey NM et al. Stimulation of Kv1.3 potassium channels by death receptors during apoptosis in Jurkat T lymphocytes.
J. Biol. Chem., 2003 Aug 29 , 278 (33319-26).

533

M'Barek S et al. A maurotoxin with constrained standard disulfide bridging: innovative strategy of chemical synthesis, pharmacology, and docking on K+ channels.
J. Biol. Chem., 2003 Aug 15 , 278 (31095-104).

534

Gao YD et al. Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: selectivity between voltage-gated and Maxi-K channels.
Proteins, 2003 Aug 1 , 52 (146-54).

535

Matkó J K+ channels and T-cell synapses: the molecular background for efficient immunomodulation is shaping up.
Trends Pharmacol. Sci., 2003 Aug , 24 (385-9).

536

Fraser SP et al. Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation.
Pflugers Arch., 2003 Aug , 446 (559-71).

537

Lang F et al. Regulation of channels by the serum and glucocorticoid-inducible kinase - implications for transport, excitability and cell proliferation.
Cell. Physiol. Biochem., 2003 , 13 (41-50).

538

Abdul M et al. Voltage-gated potassium ion channels in colon cancer.
Oncol. Rep., 2002 Sep-Oct , 9 (961-4).

539

Zaki A et al. Rapid neuromodulation by cortisol in the rat paraventricular nucleus: an in vitro study.
Br. J. Pharmacol., 2002 Sep , 137 (87-97).

540

Jiang B et al. Endogenous Kv channels in human embryonic kidney (HEK-293) cells.
Mol. Cell. Biochem., 2002 Sep , 238 (69-79).

541

Lanigan MD et al. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.
Biochemistry, 2002 Oct 8 , 41 (11963-71).

542

Liu QH et al. Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation.
J. Exp. Med., 2002 Oct 7 , 196 (897-909).

543

Pollock NS et al. Expression of voltage-dependent potassium channels in the developing visual system of Xenopus laevis.
J. Comp. Neurol., 2002 Oct 28 , 452 (381-91).

544

Fu W et al. Brownian dynamics simulations of the recognition of the scorpion toxin maurotoxin with the voltage-gated potassium ion channels.
Biophys. J., 2002 Nov , 83 (2370-85).

545

Smith GA et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells.
J. Biol. Chem., 2002 May 24 , 277 (18528-34).

546

Alessandri-Haber N et al. Molecular determinants of emerging excitability in rat embryonic motoneurons.
J. Physiol. (Lond.), 2002 May 15 , 541 (25-39).

547

Strauss O et al. Effects of protein kinase C on delayed rectifier K+ channel regulation by tyrosine kinase in rat retinal pigment epithelial cells.
Invest. Ophthalmol. Vis. Sci., 2002 May , 43 (1645-54).

548

Jespersen T et al. Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.
BioTechniques, 2002 Mar , 32 (536-8, 540).

549

Schmalhofer WA et al. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.
Biochemistry, 2002 Jun 18 , 41 (7781-94).

550

Zhou ZH et al. Incomplete inactivation of voltage-dependent K+ channels in human B lymphoma cells.
J. Membr. Biol., 2002 Jul 15 , 188 (97-105).

551

Tucker K et al. Neurotrophin modulation of voltage-gated potassium channels in rat through TrkB receptors is time and sensory experience dependent.
J. Physiol. (Lond.), 2002 Jul 15 , 542 (413-29).

552

Bock J et al. Actinomycin D-induced apoptosis involves the potassium channel Kv1.3.
Biochem. Biophys. Res. Commun., 2002 Jul 12 , 295 (526-31).

553

Artym VV et al. Molecular proximity of Kv1.3 voltage-gated potassium channels and beta(1)-integrins on the plasma membrane of melanoma cells: effects of cell adherence and channel blockers.
J. Gen. Physiol., 2002 Jul , 120 (29-37).

554

Thorne GD et al. Hypoxic vasorelaxation inhibition by organ culture correlates with loss of Kv channels but not Ca(2+) channels.
Am. J. Physiol. Heart Circ. Physiol., 2002 Jul , 283 (H247-53).

555

Feld Y et al. Electrophysiological modulation of cardiomyocytic tissue by transfected fibroblasts expressing potassium channels: a novel strategy to manipulate excitability.
Circulation, 2002 Jan 29 , 105 (522-9).

556

Mason DE et al. Molecular basis of voltage-dependent potassium currents in porcine granulosa cells.
Mol. Pharmacol., 2002 Jan , 61 (201-13).

557

Chittajallu R et al. Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle.
Proc. Natl. Acad. Sci. U.S.A., 2002 Feb 19 , 99 (2350-5).

558

Gamper N et al. IGF-1 up-regulates K+ channels via PI3-kinase, PDK1 and SGK1.
Pflugers Arch., 2002 Feb , 443 (625-34).

559

Wärntges S et al. Cerebral localization and regulation of the cell volume-sensitive serum- and glucocorticoid-dependent kinase SGK1.
Pflugers Arch., 2002 Feb , 443 (617-24).

560

Kupper J et al. Recombinant Kv1.3 potassium channels stabilize tonic firing of cultured rat hippocampal neurons.
Pflugers Arch., 2002 Feb , 443 (541-7).

561

Legros C et al. Engineering-specific pharmacological binding sites for peptidyl inhibitors of potassium channels into KcsA.
Biochemistry, 2002 Dec 24 , 41 (15369-75).

562

Batista CV et al. Two novel toxins from the Amazonian scorpion Tityus cambridgei that block Kv1.3 and Shaker B K(+)-channels with distinctly different affinities.
Biochim. Biophys. Acta, 2002 Dec 16 , 1601 (123-31).

563

Abdul M et al. Expression and activity of potassium ion channels in human prostate cancer.
Cancer Lett., 2002 Dec 1 , 186 (99-105).

564

Lu Y et al. Contributions of Kv1.2, Kv1.5 and Kv2.1 subunits to the native delayed rectifier K(+) current in rat mesenteric artery smooth muscle cells.
Life Sci., 2002 Aug 9 , 71 (1465-73).

565

Kurata HT et al. Amino-terminal determinants of U-type inactivation of voltage-gated K+ channels.
J. Biol. Chem., 2002 Aug 9 , 277 (29045-53).

566

Srinivasan KN et al. kappa-Hefutoxin1, a novel toxin from the scorpion Heterometrus fulvipes with unique structure and function. Importance of the functional diad in potassium channel selectivity.
J. Biol. Chem., 2002 Aug 16 , 277 (30040-7).

567

Teisseyre A et al. Inhibition of the activity of T lymphocyte Kv1.3 channels by extracellular zinc.
Biochem. Pharmacol., 2002 Aug 15 , 64 (595-607).

568

Cook KK et al. Two adaptor proteins differentially modulate the phosphorylation and biophysics of Kv1.3 ion channel by SRC kinase.
J. Biol. Chem., 2002 Apr 12 , 277 (13268-80).

569

Huys I et al. Purification, characterization and biosynthesis of parabutoxin 3, a component of Parabuthus transvaalicus venom.
Eur. J. Biochem., 2002 Apr , 269 (1854-65).

570

Davies AM et al. Potassium channel KV alpha1 subunit expression and function in human detrusor muscle.
J. Urol., 2002 Apr , 167 (1881-6).

571

Petty HR et al. Interactions of integrins with their partner proteins in leukocyte membranes.
Immunol. Res., 2002 , 25 (75-95).

572

Teisseyre A et al. The influence of membrane lipid metabolites on lymphocyte potassium channel activity.
Cell. Mol. Biol. Lett., 2002 , 7 (1095-109).

573

Vianna-Jorge R et al. WIN 17317-3 blocks Ca2+-activated K+ channels and enhances motility of guinea-pig detrusor muscle.
Eur. J. Pharmacol., 2001 Sep 28 , 428 (45-9).

574

Lu J et al. T1-T1 interactions occur in ER membranes while nascent Kv peptides are still attached to ribosomes.
Biochemistry, 2001 Sep 18 , 40 (10934-46).

575

Mullmann TJ et al. Insights into alpha-K toxin specificity for K+ channels revealed through mutations in noxiustoxin.
Biochemistry, 2001 Sep 18 , 40 (10987-97).

576

Yeung CH et al. Effects of the ion-channel blocker quinine on human sperm volume, kinematics and mucus penetration, and the involvement of potassium channels.
Mol. Hum. Reprod., 2001 Sep , 7 (819-28).

577

Fischer BS et al. Capsaicin inhibits Jurkat T-cell activation by blocking calcium entry current I(CRAC).
J. Pharmacol. Exp. Ther., 2001 Oct , 299 (238-46).

578

Lu J et al. Pegylation: a method for assessing topological accessibilities in Kv1.3.
Biochemistry, 2001 Nov 6 , 40 (13288-301).

579

Thorneloe KS et al. Molecular composition of 4-aminopyridine-sensitive voltage-gated K(+) channels of vascular smooth muscle.
Circ. Res., 2001 Nov 23 , 89 (1030-7).

580

Beeton C et al. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Proc. Natl. Acad. Sci. U.S.A., 2001 Nov 20 , 98 (13942-7).

581

McDaniel SS et al. Anorexic effect of K+ channel blockade in mesenteric arterial smooth muscle and intestinal epithelial cells.
J. Appl. Physiol., 2001 Nov , 91 (2322-33).

582

Cox RH et al. Differential expression of voltage-gated K(+) channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats.
Hypertension, 2001 May , 37 (1315-22).

583

Komarova SV et al. Osteoclast ion channels: potential targets for antiresorptive drugs.
Curr. Pharm. Des., 2001 May , 7 (637-54).

584

Chung S et al. Beta-amyloid peptide induces the expression of voltage dependent outward rectifying K+ channels in rat microglia.
Neurosci. Lett., 2001 Mar 9 , 300 (67-70).

585

Visentin S et al. Altered outward-rectifying K(+) current reveals microglial activation induced by HIV-1 Tat protein.
Glia, 2001 Mar 1 , 33 (181-90).

586

Hinck D et al. Gallamine triethiodide selectively blocks voltage-gated potassium channels in Ranvier nodes.
Gen. Physiol. Biophys., 2001 Mar , 20 (83-95).

587

Varga Z et al. Multiple binding sites for melatonin on Kv1.3.
Biophys. J., 2001 Mar , 80 (1280-97).

588

Cukovic D et al. A discrete amino terminal domain of Kv1.5 and Kv1.4 potassium channels interacts with the spectrin repeats of alpha-actinin-2.
FEBS Lett., 2001 Jun 1 , 498 (87-92).

589

Kuryshev YA et al. KChAP/Kvbeta1.2 interactions and their effects on cardiac Kv channel expression.
Am. J. Physiol., Cell Physiol., 2001 Jul , 281 (C290-9).

590

Singh SB et al. Candelalides A-C: novel diterpenoid pyrones from fermentations of Sesquicillium candelabrum as blockers of the voltage-gated potassium channel Kv1.3.
Org. Lett., 2001 Jan 25 , 3 (247-50).

591

Beeton C et al. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
J. Immunol., 2001 Jan 15 , 166 (936-44).

592

Jäger H et al. Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH.
FEBS Lett., 2001 Jan 12 , 488 (45-50).

593

Péter M et al. Effects of toxins Pi2 and Pi3 on human T lymphocyte Kv1.3 channels: the role of Glu7 and Lys24.
J. Membr. Biol., 2001 Jan 1 , 179 (13-25).

594

Carlier E et al. Disulfide bridge reorganization induced by proline mutations in maurotoxin.
FEBS Lett., 2001 Feb 2 , 489 (202-7).

595

Lanigan MD et al. Designed peptide analogues of the potassium channel blocker ShK toxin.
Biochemistry, 2001 Dec 25 , 40 (15528-37).

596

Fathi H B et al. The facilitatory actions of snake venom phospholipase A(2) neurotoxins at the neuromuscular junction are not mediated through voltage-gated K(+) channels.
Toxicon, 2001 Dec , 39 (1871-82).

597

Kourrich S et al. Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats.
Behav. Brain Res., 2001 Apr 8 , 120 (35-46).

598

Choi J et al. Inhibition of Kv1.3 channels by H-89 (N--[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide) independent of protein kinase A.
Biochem. Pharmacol., 2001 Apr 15 , 61 (1029-32).

599

Butenschön I et al. Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3.
J. Med. Chem., 2001 Apr 12 , 44 (1249-56).

600

Khanna R et al. K+ channels and the microglial respiratory burst.
Am. J. Physiol., Cell Physiol., 2001 Apr , 280 (C796-806).

601

Su J et al. The expression and regulation of depolarization-activated K+ channels in the insulin-secreting cell line INS-1.
Pflugers Arch., 2001 Apr , 442 (49-56).

602

Chang MC et al. Regulation of Kv1.3 channels in activated human T lymphocytes by Ca(2+)-dependent pathways.
Cell. Physiol. Biochem., 2001 , 11 (123-34).

603

Geib S et al. A novel Xenopus oocyte expression system based on cytoplasmic coinjection of T7-driven plasmids and purified T7-RNA polymerase.
Recept. Channels, 2001 , 7 (331-43).

604

Schilling T et al. Upregulation of Kv1.3 K(+) channels in microglia deactivated by TGF-beta.
Am. J. Physiol., Cell Physiol., 2000 Oct , 279 (C1123-34).

605

Ghanshani S et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
J. Biol. Chem., 2000 Nov 24 , 275 (37137-49).

606

Ouadid-Ahidouch H et al. KV1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation.
Biochem. Biophys. Res. Commun., 2000 Nov 19 , 278 (272-7).

607

Péter M et al. Blockage of human T lymphocyte Kv1.3 channels by Pi1, a novel class of scorpion toxin.
Biochem. Biophys. Res. Commun., 2000 Nov 11 , 278 (34-7).

608

Kuryshev YA et al. KChAP as a chaperone for specific K(+) channels.
Am. J. Physiol., Cell Physiol., 2000 May , 278 (C931-41).

609

Lecomte C et al. Maurotoxin and the Kv1.1 channel: voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys31-Cys34.
J. Pept. Res., 2000 Mar , 55 (246-54).

610

Wulfsen I et al. Expression of mRNA for voltage-dependent and inward-rectifying K channels in GH3/B6 cells and rat pituitary.
J. Neuroendocrinol., 2000 Mar , 12 (263-72).

611

Legros C et al. Generating a high affinity scorpion toxin receptor in KcsA-Kv1.3 chimeric potassium channels.
J. Biol. Chem., 2000 Jun 2 , 275 (16918-24).

612

Cayabyab FS et al. Suppression of the rat microglia Kv1.3 current by src-family tyrosine kinases and oxygen/glucose deprivation.
Eur. J. Neurosci., 2000 Jun , 12 (1949-60).

613

Lang R et al. KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels.
Am. J. Physiol. Renal Physiol., 2000 Jun , 278 (F1013-21).

614

Madeja M et al. Sensitivity of native and cloned hippocampal delayed-rectifier potassium channels to verapamil.
Neuropharmacology, 2000 Jan 4 , 39 (202-10).